Information Provided By:
Fly News Breaks for January 22, 2020
Jan 22, 2020 | 05:18 EDT
UBS analyst Navin Jacob downgraded BioNTech to Neutral from Buy with an increased price target of $35. The analyst sees a full valuation and more balanced risk/reward profile with the stock up 120% since the initial public offering.